Cargando…
Safe Use of Nivolumab in a Patient with Epipharyngeal Carcinoma and Preexisting Ulcerative Colitis: A Histologically Proven Case Report
Nivolumab, an antibody against human programmed cell death 1 (PD-1), enhances pre-existing immune responses and has antitumor activity. However, it may also cause undesirable immune-related adverse events (irAEs), such as anti-PD-1-related colitis. In addition, Nivolumab can worsen pre-existing auto...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society of Internal Medicine
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7205527/ https://www.ncbi.nlm.nih.gov/pubmed/32009094 http://dx.doi.org/10.2169/internalmedicine.3901-19 |
_version_ | 1783530255670050816 |
---|---|
author | Hijikata, Yasuki Matsubara, Yasuo Ota, Yasunori Lim, Lay Ahyoung Tani, Kenzaburo Hirata, Yoshihiro Yotsuyanagi, Hiroshi |
author_facet | Hijikata, Yasuki Matsubara, Yasuo Ota, Yasunori Lim, Lay Ahyoung Tani, Kenzaburo Hirata, Yoshihiro Yotsuyanagi, Hiroshi |
author_sort | Hijikata, Yasuki |
collection | PubMed |
description | Nivolumab, an antibody against human programmed cell death 1 (PD-1), enhances pre-existing immune responses and has antitumor activity. However, it may also cause undesirable immune-related adverse events (irAEs), such as anti-PD-1-related colitis. In addition, Nivolumab can worsen pre-existing autoimmune diseases. Ulcerative colitis (UC) is a chronic inflammatory disease of the colon. Its exact cause is unknown, but it may involve the dysregulation of the mucosal immune response. Thus, it is of great interest whether nivolumab can affect UC activity. This is the first report of a patient with epipharyngeal carcinoma and ulcerative colitis who was confirmed to have been safely treated with nivolumab based on autopsy findings. |
format | Online Article Text |
id | pubmed-7205527 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | The Japanese Society of Internal Medicine |
record_format | MEDLINE/PubMed |
spelling | pubmed-72055272020-05-12 Safe Use of Nivolumab in a Patient with Epipharyngeal Carcinoma and Preexisting Ulcerative Colitis: A Histologically Proven Case Report Hijikata, Yasuki Matsubara, Yasuo Ota, Yasunori Lim, Lay Ahyoung Tani, Kenzaburo Hirata, Yoshihiro Yotsuyanagi, Hiroshi Intern Med Case Report Nivolumab, an antibody against human programmed cell death 1 (PD-1), enhances pre-existing immune responses and has antitumor activity. However, it may also cause undesirable immune-related adverse events (irAEs), such as anti-PD-1-related colitis. In addition, Nivolumab can worsen pre-existing autoimmune diseases. Ulcerative colitis (UC) is a chronic inflammatory disease of the colon. Its exact cause is unknown, but it may involve the dysregulation of the mucosal immune response. Thus, it is of great interest whether nivolumab can affect UC activity. This is the first report of a patient with epipharyngeal carcinoma and ulcerative colitis who was confirmed to have been safely treated with nivolumab based on autopsy findings. The Japanese Society of Internal Medicine 2020-02-01 2020-04-15 /pmc/articles/PMC7205527/ /pubmed/32009094 http://dx.doi.org/10.2169/internalmedicine.3901-19 Text en Copyright © 2020 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Case Report Hijikata, Yasuki Matsubara, Yasuo Ota, Yasunori Lim, Lay Ahyoung Tani, Kenzaburo Hirata, Yoshihiro Yotsuyanagi, Hiroshi Safe Use of Nivolumab in a Patient with Epipharyngeal Carcinoma and Preexisting Ulcerative Colitis: A Histologically Proven Case Report |
title | Safe Use of Nivolumab in a Patient with Epipharyngeal Carcinoma and Preexisting Ulcerative Colitis: A Histologically Proven Case Report |
title_full | Safe Use of Nivolumab in a Patient with Epipharyngeal Carcinoma and Preexisting Ulcerative Colitis: A Histologically Proven Case Report |
title_fullStr | Safe Use of Nivolumab in a Patient with Epipharyngeal Carcinoma and Preexisting Ulcerative Colitis: A Histologically Proven Case Report |
title_full_unstemmed | Safe Use of Nivolumab in a Patient with Epipharyngeal Carcinoma and Preexisting Ulcerative Colitis: A Histologically Proven Case Report |
title_short | Safe Use of Nivolumab in a Patient with Epipharyngeal Carcinoma and Preexisting Ulcerative Colitis: A Histologically Proven Case Report |
title_sort | safe use of nivolumab in a patient with epipharyngeal carcinoma and preexisting ulcerative colitis: a histologically proven case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7205527/ https://www.ncbi.nlm.nih.gov/pubmed/32009094 http://dx.doi.org/10.2169/internalmedicine.3901-19 |
work_keys_str_mv | AT hijikatayasuki safeuseofnivolumabinapatientwithepipharyngealcarcinomaandpreexistingulcerativecolitisahistologicallyprovencasereport AT matsubarayasuo safeuseofnivolumabinapatientwithepipharyngealcarcinomaandpreexistingulcerativecolitisahistologicallyprovencasereport AT otayasunori safeuseofnivolumabinapatientwithepipharyngealcarcinomaandpreexistingulcerativecolitisahistologicallyprovencasereport AT limlayahyoung safeuseofnivolumabinapatientwithepipharyngealcarcinomaandpreexistingulcerativecolitisahistologicallyprovencasereport AT tanikenzaburo safeuseofnivolumabinapatientwithepipharyngealcarcinomaandpreexistingulcerativecolitisahistologicallyprovencasereport AT hiratayoshihiro safeuseofnivolumabinapatientwithepipharyngealcarcinomaandpreexistingulcerativecolitisahistologicallyprovencasereport AT yotsuyanagihiroshi safeuseofnivolumabinapatientwithepipharyngealcarcinomaandpreexistingulcerativecolitisahistologicallyprovencasereport |